The US Food and Drug Administration has approved a move to make the oral lead-in period for ViiV Healthcare’s once-every-other-month drug Cabenuva optional.
A representative from the HIV-centered pharmaceutical company shares thoughts and perspective on the every-two-month treatment and how it might help patients.
The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.
It has been a pleasure for the OSP team to connect with a long list of fascinating industry minds and share the stories; here are a few of our favorites.
The HIV treatment specialist has sent an application to the agency for tolutegravir, a single-tablet treatment indicated for children living with the virus.
June 2021 marks the 40th anniversary of the publication of the first reported cases of AIDS in the US. A session at BIO Digital – featuring Dr. Anthony Fauci, Director of NIAID at the NIH – will focus on four decades of innovation as well as the critical...
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
GSK’s Dovato is approved by the US FDA for the treatment of individuals with HIV with no previous antiretroviral therapy, in a first for a two-drug, fixed-dose, complete regimen.
SRI International was awarded a seven-year, $49m contract from the NIAID (National Institute of Allergy and Infectious Diseases), which is a division of the NIH (National Institutes of Health), for preclinical HIV/AIDS work.
Lonza has denied reports it has signed a deal with the South African government to build a $210m (€159m) API plant, saying it is merely “in discussions” over plans.
Research into developing manufacturing methods to produce cheap antiretrovirals in Africa has been highlighted on World Aids Day by The Council for Scientific and Industrial Research (CSIR).
Switzerland-based Roche is helping African nations fight the AIDS
epidemic by sharing its coveted saquinavir drug-producing
technology with two more manufacturers in Ethiopia and Zimbabwe.
The significance of the aborted deal between GlaxoSmithKline and
Cobra has been exaggerated due to GSK's high profile and is not the
end of the world, the British contract manufacturer said.
A naturally occurring molecule helps protect the immune system from
being destroyed by HIV and could open up a new way of fighting the
effects of the virus, according to new research.
According to the results of a new survey HIV patients are in the
dark about treatment options and the significance of drug
resistance, not only jeopardising their own health but also
potentially exacerbating the problem of limited...
Scientists believe they have made a breakthrough in the fight
against HIV drug resistance by developing a drug that is the first
in a new class of HIV drug candidates called Maturation Inhibitors.
Biopharmaceuticals manufacturer Cobra will provide process
development and manufacturing of two HIV vaccine candidates for
evaluation in clinical trials under an agreement with the
International AIDS Vaccine Initiative (IAVI) and...
Scientists have taken a major step forward in the diagnosis and
treatment of HIV as it was revealed that the virus' 3D structure
had been constructed. This achievement will prove instrumental in
the development of more effective...
AIDS researchers have uncovered new evidence, which points to the
'fitness' of the HIV virus as a primary factor in explaining
different resistant patterns to the drugs that treat the disease.
According to new study, the virus that causes AIDS is becoming more
sensitive to drug treatments, contradicting a wealth of research
that demonstrates the emergence of drug resistant viral strains.
Researchers have helped pioneer a novel approach to the development
and delivery of an HIV/AIDS vaccine, which involves a
female-controlled vaginal HIV vaccine. The novel method is to be
tried in order to break the infection cycle...
VIRxSYS has announced the completion of the phase I study of its
novel HIV gene therapy, which has been touted as the first of a
next-generation anti-HIV treatment involving gene therapy. The
positive results mean a phase II study...
The first documented case of drug resistant HIV has prompted calls
to step up HIV drug research after the victim developed full-blown
AIDS in just three months.
India begins its first ever human clinical trial of an
investigational vaccine candidate designed to treat HIV/AIDS, which
now has a worldwide infection rate of 14,000 every day.
Global efforts to develop a vaccine to treat HIV infection could be
derailed because investigators have not considered manufacturing
processes in the design of their candidates.
